Dr. Philip Bentley
Dr. Philip Bentley, a biochemist, boasts over 40 years of experience in drug metabolism and toxicology. After wrapping up his postdoctoral work at the University of Basel in Switzerland and the University of Mainz in Germany, he made a significant career move in 1979. He joined the Ciba – Geigy Central Toxicology Group, which later […]
Dr. Thomas Hohman
Dr. Thomas Hohman has an illustrious career in the realm of ophthalmology and pharmaceutical research. He previously served as Head of Retina Discovery and Vice President of Retina Translation Medicine at Allergan. In this capacity, he played a pivotal role in uncovering and driving forward innovative treatments for a range of retinal diseases, with a […]
Dr. Matthias Staufenbiel
Dr. Matthias Staufenbiel, a neuroscientist, is currently a Research Consultant at the Hertie Institute for Clinical Brain Research, University of Tübingen. Between 1988 to 2012, Dr Staufenbiel held leading positions in Novartis and Sandoz, focusing on neurodegeneration, especially Alzheimer’s disease in preclinical neuroscience research. Before that, he had an independent research position at the Max […]
Dr. Hans-Jürgen Pfannkuche
Pharmacovigilance Professional and Preclinical & Clinical Pharmacologist with 35 years of Team & Project Lead Expertise and thorough Experience in Drug Safety (incl. Development & Validation of GxP – conform IT systems), Drug Discovery & Development, and Registration Affairs. Former employee at Novartis Pharma AG, CH-4002 Basel, Switzerland (Sandoz Pharma AG prior to the creation […]
Dr. Kin-Sang (Anson) Cho
Dr. Kin – Sang (Anson) Cho is currently an Investigator at the Schepens Eye Research Institute and an Instructor at Harvard Medical School. He has dedicated his career to researching the mechanisms of degeneration and regeneration in the mammalian retina, with a long – term goal of developing novel therapeutic strategies for retinal degenerative diseases […]
